Market Research Report
Cryptosporidiosis - Pipeline Review, H2 2019
|Published by||Global Markets Direct||Product code||321928|
|Published||Content info||30 Pages
Delivery time: 1-2 business days
|Cryptosporidiosis - Pipeline Review, H2 2019|
|Published: December 27, 2019||Content info: 30 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cryptosporidiosis - Pipeline Review, H2 2019, provides an overview of the Cryptosporidiosis (Infectious Disease) pipeline landscape.
Cryptosporidiosis is an intestinal illness caused by a microscopic parasite called Cryptosporidium. Symptoms include watery diarrhea, dehydration, and lack of appetite, weight loss, fever, nausea and vomiting. Risk factors include contaminated water, animal handlers and parents of infected children.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cryptosporidiosis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Cryptosporidiosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cryptosporidiosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cryptosporidiosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 3 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.
Cryptosporidiosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.